Sotorasib Alternatives: How It Compares to Other KRAS G12C Inhibitors

Sotorasib vs Adagrasib (Krazati)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06497556) enrolling 338 participants, primary completion 2027-09.

Primary-endpoint values for NCT06497556 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Sotorasib vs Docetaxel (Taxotere)

No head-to-head Phase-3 trial directly compares Sotorasib with Docetaxel.

Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.

Sotorasib vs Pembrolizumab (Keytruda)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT05920356) enrolling 750 participants, primary completion 2027-06.

Primary-endpoint values for NCT05920356 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Several investigational agents are currently in active Phase 3 development. These include Pemetrexed from Eli Lilly and Company, with its lead Phase 3 trial identified as NCT00078260. Another agent, Divarasib by Hoffmann-La Roche, is also undergoing Phase 3 evaluation, detailed in its lead study NCT03178552. Additionally, Calderasib from Merck Sharp & Dohme LLC is progressing through Phase 3, with its primary trial listed as NCT06345729.

For patients with a confirmed KRAS G12C mutation, a targeted therapy such as Sotorasib may be a primary consideration. As a specific KRAS G12C inhibitor, its mechanism directly addresses this oncogenic driver, distinguishing it from broader approaches like chemotherapy or PD-1 inhibition. The availability of an oral dosing regimen for a KRAS G12C inhibitor can offer convenience compared to intravenously administered treatments, potentially improving patient adherence and quality of life.

Alternative treatment options may be preferred based on various clinical factors. Another KRAS G12C inhibitor, Adagrasib, offers an objective response rate of 43% with a dosing of 600 mg orally twice daily, providing an alternative targeted oral option. For patients where targeted therapy is not suitable or has been exhausted, chemotherapy agents like Docetaxel (75 mg/m2 intravenously every 3 weeks) may be considered, often with a longer track record in various cancer types and potentially different cost profiles. Immunotherapy with a PD-1 inhibitor such as Pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks intravenously) may be chosen for specific patient subgroups, particularly given its reported Overall Survival Hazard Ratio of 0.6 at 5 years in relevant populations, and its distinct mechanism of action.

This information is for educational purposes only and does not constitute medical advice. Clinical decisions regarding patient care must always be made by a qualified healthcare provider.